Skip to main content

Specialty Pharmacy

  • Giant Eagle acquires Rx21 Specialty Pharmacy, enabling enhanced hepatitis C/organ transplant services

    PITTSBURGH — Giant Eagle on Monday announced the acquisition of Rx21 Specialty Pharmacy, enabling the company to provide enhanced services to Hepatitis C and organ transplant patients and providers.

  • Reports: Patients reported as cured of HIV experience return of virus

    NEW YORK — Two patients in Boston whom researchers had thought were cured of HIV have experienced a relapse of the infection, according to published reports.

    The New York Daily News reported that the two men, who were believed cured after receiving bone marrow transplants for lymphoma, had the virus return.

  • Teva launches imiquimod cream

    NORTH WALES, Pa. — Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

    Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.'s Aldara.

    The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

     

  • Newly approved hepatitis C treatment by Gilead Sciences said to offer major advance in treatment

    FOSTER CITY, Calif. — The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

  • FDA approves first drug for Peyronie's disease

    SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

  • Mylan completes acquisition of Agila from Strides Arcolab

    PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

    Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.

  • FDA issues rules for sterile compounding pharmacies

    NEW YORK — Compounding pharmacies that produce sterile drugs can register as outsourcing facilities and may be exempt from certain Food and Drug Administration approval requirements, according to a document published on the FDA's website.

  • Reports: Drug industry organizations sue Seattle-area county government over drug-disposal ordinance

    NEW YORK — Four drug industry trade groups are suing the board of health in King County, Wash., over a local health ordinance that they say shifts the burden of sustainable disposal of unwanted drugs onto drug companies, according to published reports.

X
This ad will auto-close in 10 seconds